“Pharma Bro” Martin Shkreli is blatantly violating his court-ordered lifetime ban from the pharmaceutical industry by trading stocks and boasting about his market bets on social media, the feds and local prosecutors say.
asserted
feds → violate → media
The Federal Trade Commission and six state attorneys general demanded Tuesday that a federal judge hold the ex-con Shkreli in contempt and force him to surrender his trading profits and any pharmaceutical stocks he still owns.
asserted
he → demand → profits
Despite his 2022 lifetime ban stemming from his notorious fraud conviction — and a nearly $65 million judgment in that case — Shkreli, 43, has been calling himself “the GOAT of binary events,” bragging to his social media followers that “[t]he last time I shorted a stock, I made $20 million bucks,” according to court documents.
uncertain
I → stem → documents
The feds claim Shkreli, who named his newborn son Torque “EZMONEY$TAXX” Shkreli last year, began his “brazen violations” shortly after leaving prison in 2022 following his securities fraud conviction — livestreaming stock trades on his YouTube channel despite being barred from participating in the drug industry.
uncertain
who → claim → industry
Shkreli became notorious in 2015 when his company, Turing Pharmaceuticals, remorselessly jacked up the price of the lifesaving antiparasitic drug Daraprim from $17.50 to $750 a pill.
asserted
company → become → 750
He was later ordered to return $64.6 million he made on the drug, a sum that remains unpaid, according to authorities.
uncertain
that → order → authorities
In 2017, Shkreli was convicted of fraud and conspiracy for looting Retrophin, a drug company he founded.
asserted
he → convict → Retrophin
After serving most of a seven-year sentence, he was slapped with the lifetime industry ban in February 2022.
asserted
he → serve → February
Most recently, to bolster his bets against small biotech firms, Shkreli devoted hours to trashing their experimental treatments and urging viewers to “short this stock,” the feds said.
asserted
feds → bolster → stock
In one instance, Shkreli allegedly targeted Cassava Sciences, a company developing an Alzheimer’s treatment, ahead of disappointing clinical trial results in November 2024.
uncertain
Shkreli → target → November
His brokerage account subsequently ballooned to $841,000 from $138,200 shortly before the announcement — bringing a gain of more than $700,000, authorities said, although they did not attribute the entire increase to his Cassava bet.
asserted
they → balloon → bet
The feds alleged that Shkreli has traded shares in more than 60 pharmaceutical companies since July 2022, including Pfizer, Moderna, Eli Lilly and Novo Nordisk.
“I’m showing you how to trade and invest in biotech,” he told viewers in April 2025, explaining his “magic trick:” “It doesn’t matter what trades I make because I can always find a couple of biotech stocks to smoke.”
The convicted fraudster even boasted about his ability to move markets, remarking that one biotech firm’s stock “dropped a bunch since I recommended the short.”
asserted
I → allege → short
In November 2025, Shkreli announced that he was betting against Capricor Therapeutics, a biotech developing an experimental treatment for Duchenne muscular dystrophy.
asserted
he → announce → dystrophy
Its stock immediately plunged 17% following his public warning, according to the filing.
uncertain
stock → plunge → filing
But the trade backfired the following month when Capricor announced positive clinical trial results, sending its shares soaring more than 370%, the feds said.
Shkreli, who had gone all-in on the bet, later acknowledged that his trading account had been wiped out.
asserted
account → backfire → bet
“It’s over for the Schwab account,” he told viewers, according to the filing.
uncertain
he → ’ → filing
Regulators also flagged a new trading challenge Shkreli launched in June involving a portfolio with a reported starting balance of $10 million.
asserted
Shkreli → flag → million
The authorities suspect his publicly disclosed trades represent only a fraction of his activity, citing references to several other brokerage accounts.
“
asserted
trades → suspect → accounts
I have some other accounts that I’[d] show you, but, like, I know feds are watching, so f–k that,” Shkreli said during one livestream cited in the court papers.
asserted
Shkreli → have → papers
The filing also identifies Shkreli’s significant other, Chelsea Voss, and his sister, Leonora Izerne, as people who appear to have helped facilitate his trading.
asserted
who → identify → trading
Start your day with all you need to know
Morning Report delivers the latest news, videos, photos and more.
asserted
Report → start → news
In one livestream, Shkreli allegedly asked Voss for $30,000 to cover a potential margin call.
uncertain
Shkreli → ask → call
Regulators want both women ordered to preserve evidence related to his transactions.
asserted
women → want → transactions
The FTC and prosecutors including New York AG Letitia James are demanding that Shkreli provide a sworn accounting of all his pharmaceutical stock trades since February 2022 and submit to a financial audit at his own expense.
They also want a court-imposed penalty equal to his profits from those trades, plus interest, without allowing him to deduct losses from losing bets.
asserted
him → include → bets
Regulators are urging US District Judge Denise Cote to establish escalating penalties, including additional fines and possible incarceration, if Shkreli fails to comply with the court’s orders or continues violating the ban.
asserted
Shkreli → urge → ban
The ban was upheld by a federal appeals court in January 2024, and the Supreme Court declined to review his case later that year.
asserted
Court → uphold → case
Shkreli, who was separately sentenced to seven years in prison for securities fraud, was released in 2022.
asserted
who → sentence → 2022
The Post has sought comment from Shkreli and his attorney.
asserted
Post → seek → Shkreli
The Aporia
